Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization

Celli, Jonathan P.; Spring, Bryan Q.; Rizvi, Imran; Evans, Conor L.; Samkoe, Kimberley S.; Verma, Sarika; Pogue, Brian W.; Hasan, Tayyaba

doi:10.1021/cr900300p

Cited by 2,134 publications

(1,684 citation statements)

References 396 publications

(892 reference statements)

Supporting

Mentioning

1,657

Contrasting

Unclassified

Order By: Relevance

“…We expect this could increase the efficacy of such treatments. Most photosensitizers of photodynamic therapy have to be activated using light in the nearinfrared range [1][2][3]. However, porphyrin compounds, the drugs that are most commonly used in photodynamic therapy, exhibit stronger absorption and excitation in the range of 400-600 nm [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Photoactivation Without “Light”: Use of Cherenkov Radiation to Overcome the Penetration Limit of Light

et al. 2011

View full text Add to dashboard Cite

Purpose: The poor tissue penetration of visible light has been a major barrier for optical imaging, photoactivatable conversions, and photodynamic therapy for in vivo targets with depths beyond 10 mm. In this report, as a proof-of-concept, we demonstrated that a positron emission tomography (PET) radiotracer, 2-deoxy-2-[ 18 F]fluoro-D-glucose ( 18 FDG), could be used as an alternative light source for photoactivation. Procedures: We utilized 18 FDG, which is a metabolic activity-based PET probe, as a source of light to photoactivate caged luciferin in a breast cancer animal model expressing luciferase. Results: Bioluminescence produced from luciferin allowed for the real-time monitoring of Cherenkov radiation-promoted uncaging of the substrate. Conclusion: The proposed method may provide a very important option for in vivo photoactivation, in particular for activation of photosensitizers for photodynamic therapy and eventually for combining radioisotope therapy and photodynamic therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, the poor tissue penetrating ability of light undoubtedly limits its broad application in vivo [1][2][3]. To address light penetration issues, long wavelength light sources are often used, but this can come as a tradeoff with excitation losses due to poor overlap with absorption spectra.…”

Section: Introductionmentioning

confidence: 99%

In Vivo Photoactivation Without “Light”: Use of Cherenkov Radiation to Overcome the Penetration Limit of Light

et al. 2011

View full text Add to dashboard Cite

show abstract

“…A dominant form of decay of the excited state PS is to transfer energy (sensitize) molecular oxygen so that it comes into contact with or reacts with cellular constituents generating reactive oxygen species (ROS) such as singlet oxygen and oxygen radicals (Type I & II). Singlet oxygen is highly reactive and cytotoxic, and hence causes damage to the irradiated cells eventually leading to selective apoptosis or necrosis in the treated tissue and tumour shrinkage [4,5,7,15,[18][19][20][21][22].…”

Section: Please Provide Corresponding Author(s) Photographmentioning

confidence: 99%

“…The highly reactive oxygen species (ROS) have the ability to locally destroy cancerous tissue in a patient [4,5,[7][8][9][10][11][12]. In the clinic PDT treatment commonly consists of two stages ( Figure 1B).…”

Section: Introduction To Pdtmentioning

confidence: 99%

New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons

Scherer

Bisby²,

Botchway³

et al. 2017

ACAMC

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an alternative cancer treatment to conventional surgery, radiotherapy and chemotherapy. It is based on activating a drug with light that triggers the generation of cytotoxic species that promote tumour cell killing. At present, PDT is mainly used in the treatment of wet age-related macular degeneration, for precancerous conditions of the skin (e.g. actinic keratosis) and in the palliative care of advanced cancers, for instance of the bladder or the oesophagus. Due to a lack of phase III clinical trials and limitations of light penetration to deeper lying tumours (in excess of 1 cm), PDT is still not used as a first line cancer treatment, which is surprising given the first clinical trials by Dougherty's group dating back to the 1970's. However research continues to demonstrate the potential benefits of PDT and the need to stimulate funding and uptake of clinical studies using next generation photosensitizers offering advanced targeted delivery, improved photodynamic dose combined with modern light delivery technologies. This review surveys the available PDT treatments and emerging novel developments in the field with a particular focus on two-photon techniques that are anticipated to improve the effectiveness of PDT in tissues at depth and on next generation drugs that work without the need of the presence of oxygen for photosensitization making them effective where hypoxia has taken hold.

show abstract

“…Photodynamic therapy (PDT) takes advantage of light activation to achieve spatio-temporal selectivity for cancerous tissue, thus reducing the systemic toxicity to healthy cells [16][17][18][19]. PDT has recently emerged as an alternative, and, in some cases, a superior approach to conventional dermatological therapies and for the treatment of endoscopically accessible tumours [20][21][22][23][24][25][26].…”

Section: Introductionmentioning

confidence: 99%

Photochemistry and DNA photocleavage by a new unsupported dirhodium(II,II) complex

Burya

Turró

et al. 2013

Phil. Trans. R. Soc. A.

View full text Add to dashboard Cite

One contribution of 18 to a Discussion Meeting Issue 'Photoactivatable metal complexes: from theory to applications in biotechnology and medicine' . The quantum yield for the photochemical transformation of 1 in H 2 O exceeds unity (Φ 550 nm = 1.38) indicative of dark reactions following the initial photoprocess. DNA photocleavage was observed for 1 (λ irr > 590 nm), whereas the complex is unreactive in the dark. This feature makes 1 a promising photodynamic therapy agent that does not operate via the production of singlet oxygen, 1 O 2 . Subject Areas: photochemistry Keywords

show abstract

Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization

Cited by 2,134 publications

References 396 publications

In Vivo Photoactivation Without “Light”: Use of Cherenkov Radiation to Overcome the Penetration Limit of Light

In Vivo Photoactivation Without “Light”: Use of Cherenkov Radiation to Overcome the Penetration Limit of Light

New Approaches to Photodynamic Therapy from Types I, II and III to Type IV Using One or More Photons

Photochemistry and DNA photocleavage by a new unsupported dirhodium(II,II) complex

Contact Info

Product

Resources

About